Company intelligence / Profile preview

SISCAPA Assay Technologies

Washington, District of Columbia, United States

Ownership: Private
Employees: ~20
Development stage: Other

Overview

SISCAPA Assay Technologies provides commercial immunoaffinity–mass spectrometry assay development and analytical services for quantitative measurement of protein drugs, drug targets, and biomarkers used in research, clinical trials, and some diagnostic settings; it does not develop its own therapeutics.

Modalities: ProteinDevice
Industry: Protein Biomarker Diagnostics

Partnerships

Biognosys (strategic collaboration to offer SISCAPA assays via Biognosys’ regulated proteomics CRO infrastructure)Crucial Data Solutions (remote diagnostics and longitudinal monitoring partnership, via news cited on ZoomInfo)

Beyond the preview

Go deeper on SISCAPA Assay Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SISCAPA Assay Technologies.

Explore the full profile